KYKOF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 13:51):

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...

Stats
Today's Volume	301.00
Average Volume	459.00
Market Cap	9.32B
EPS	$0 ( 2024-05-07 )
Next earnings date	( $0.00142 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	24.76
ATR14	$0 (0.00%)

Kyowa Kirin Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kyowa Kirin Co., Ltd. Financials

Annual	2023
Revenue:	$442.23B
Gross Profit:	$320.62B (72.50 %)
EPS:	$151.03

FY	2023
Revenue:	$442.23B
Gross Profit:	$320.62B (72.50 %)
EPS:	$151.03

FY	2022
Revenue:	$398.37B
Gross Profit:	$311.46B (78.18 %)
EPS:	$99.68

Financial Reports:

No articles found.

Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.